Lipigon Pharmaceuticals AB Working Capital to Net Assets Ratio
Lipigon Pharmaceuticals AB working capital to net assets ratio. Lipigon Pharmaceuticals AB (LPGO) has a Working Capital to Net Assets ratio of 96.8% as of December 2025. Working capital of Skr7.66 Million (current assets of Skr11.24 Million minus current liabilities of Skr3.57 Million) is measured against net assets of Skr7.91 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check LPGO tangible net worth ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Lipigon Pharmaceuticals AB (2017–2025)
Working capital to net assets ratio of Lipigon Pharmaceuticals AB from 2017 to 2025. This chart shows how Lipigon Pharmaceuticals AB's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2017 to 2025. As of December 2025, the ratio stands at 96.8%, reflecting working capital of Skr7.66 Million against net assets of Skr7.91 Million SEK. See Lipigon Pharmaceuticals AB defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Lipigon Pharmaceuticals AB Working Capital to Net Assets Ratio by Year (2017–2025)
Lipigon Pharmaceuticals AB working capital to net assets ratio by year from 2017 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Lipigon Pharmaceuticals AB from 2017 to 2025, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Lipigon Pharmaceuticals AB (LPGO) total assets.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 96.8% | Skr7.66 Million | Skr7.91 Million | Skr11.24 Million | Skr3.57 Million | ▼ -0.3 pp |
| 2024 | 97.1% | Skr7.54 Million | Skr7.76 Million | Skr14.60 Million | Skr7.06 Million | ▼ -2.7 pp |
| 2023 | 99.8% | Skr28.39 Million | Skr28.44 Million | Skr33.55 Million | Skr5.16 Million | ▲ +1.7 pp |
| 2022 | 98.1% | Skr3.80 Million | Skr3.87 Million | Skr10.74 Million | Skr6.95 Million | ▼ -1.4 pp |
| 2021 | 99.6% | Skr22.87 Million | Skr22.96 Million | Skr29.33 Million | Skr6.47 Million | ▼ -0.4 pp |
| 2020 | 100.0% | Skr12.98 Million | Skr12.98 Million | Skr15.24 Million | Skr2.26 Million | ▲ +0.0 pp |
| 2019 | 100.0% | Skr2.17 Million | Skr2.17 Million | Skr3.21 Million | Skr1.04 Million | ▲ +0.0 pp |
| 2018 | 100.0% | Skr-842.00K | Skr-842.00K | Skr225.00K | Skr1.07 Million | ▲ +0.0 pp |
| 2017 | 100.0% | Skr1.15 Billion | Skr1.15 Billion | Skr1.77 Billion | Skr619.85 Million | — |